Copley-Merriman C, Lair T J
Health Economics Research-Decision Sciences Division, Eli Lilly and Company, Indianapolis, Indiana.
Clin Ther. 1994 May-Jun;16(3):553-68.
This paper reviews the issues that are critical for the valuation of medical resources in the context of health economic studies. There are several points to consider when undertaking the valuation of medical resources. The perspective of the analysis should be established before determining the valuation process. Future costs should be discounted to present values, and time and effort spent in assigning a monetary value to a medical resource should be proportional to its importance in the analysis. Prices vary considerably based on location of the service and the severity of the illness episode. Because of the wide variability in pricing data, sensitivity analysis is an important component of validation of study results. A variety of data sources have been applied to the valuation of medical resources. Several types of data are reviewed in this paper, including claims data, national survey data, administrative data, and marketing research data. Valuation of medical resources collected in clinical trials is complex because of the lack of standardization of the data sources. A national pricing data source for health economic valuation would greatly facilitate study analysis and make comparisons between results more meaningful.
本文回顾了在健康经济研究背景下对医疗资源估值至关重要的问题。在对医疗资源进行估值时，有几点需要考虑。在确定估值过程之前，应确立分析的视角。未来成本应折算为现值，并且为医疗资源赋予货币价值所花费的时间和精力应与其在分析中的重要性成正比。价格会因服务地点和疾病发作的严重程度而有很大差异。由于定价数据的广泛变异性，敏感性分析是验证研究结果的重要组成部分。多种数据来源已被应用于医疗资源的估值。本文回顾了几种类型的数据，包括理赔数据、全国调查数据、行政数据和市场研究数据。由于数据源缺乏标准化，对临床试验中收集到医疗资源进行估值很复杂。用于健康经济估值的国家定价数据源将极大地促进研究分析，并使结果之间的比较更有意义。
